小分子 CXCR2 和 CXCR1 拮抗剂抑制人结肠癌肝转移。
Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.
机构信息
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA.
出版信息
Cancer Lett. 2011 Jan 28;300(2):180-8. doi: 10.1016/j.canlet.2010.10.004. Epub 2010 Oct 29.
Abstract
CXCR1 and CXCR2 are G-protein coupled receptors, that have been shown to play important role in tumor growth and metastasis, and are prime targets for the development of novel therapeutics. Here, we report that targeting CXCR2 and CXCR1 activity using orally active small molecule antagonist (SCH-527123, SCH-479833) inhibits human colon cancer liver metastasis mediated by decreased neovascularization and enhanced malignant cell apoptosis. There were no differences in primary tumor growth. These studies demonstrate the important role of CXCR2/1 in colon cancer metastasis and that inhibition of CXCR2 and CXCR1, small molecule antagonists provides a novel therapeutic strategy.
摘要
CXCR1 和 CXCR2 是 G 蛋白偶联受体，已被证明在肿瘤生长和转移中发挥重要作用，是开发新型治疗药物的主要靶点。在这里，我们报告使用口服活性小分子拮抗剂（SCH-527123、SCH-479833）靶向 CXCR2 和 CXCR1 活性可抑制 CXCR2 和 CXCR1 活性，通过减少新生血管形成和增强恶性细胞凋亡来抑制人结肠癌肝转移。原发性肿瘤生长没有差异。这些研究表明 CXCR2/1 在结肠癌转移中的重要作用，抑制 CXCR2 和 CXCR1 的小分子拮抗剂提供了一种新的治疗策略。
相似文献
1
Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.小分子 CXCR2 和 CXCR1 拮抗剂抑制人结肠癌肝转移。
Cancer Lett. 2011 Jan 28;300(2):180-8. doi: 10.1016/j.canlet.2010.10.004. Epub 2010 Oct 29.
2
A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.小分子 CXCR1 和 CXCR2 拮抗剂通过 PI3K/AKT 通路抑制黑色素瘤细胞增殖、迁移和侵袭。
Med Clin (Barc). 2019 Jun 7;152(11):425-430. doi: 10.1016/j.medcli.2018.08.006. Epub 2018 Oct 16.
3
Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.针对CXCR2和CXCR1的小分子拮抗剂通过降低肿瘤细胞增殖、存活及血管生成来抑制人黑色素瘤生长。
Clin Cancer Res. 2009 Apr 1;15(7):2380-6. doi: 10.1158/1078-0432.CCR-08-2387. Epub 2009 Mar 17.
4
The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.CXCR2 拮抗剂 SCH-527123 在临床前结肠癌模型中显示出抗肿瘤活性，并增强细胞对奥沙利铂的敏感性。
Mol Cancer Ther. 2012 Jun;11(6):1353-64. doi: 10.1158/1535-7163.MCT-11-0915. Epub 2012 Mar 5.
5
Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.拉达瑞辛，一种双CXCR1/2抑制剂，通过影响恶性细胞和肿瘤微环境，减轻携带不同分子缺陷的实验性黑色素瘤。
Oncotarget. 2017 Feb 28;8(9):14428-14442. doi: 10.18632/oncotarget.14803.
6
CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.使用CXCL8/白细胞介素-8类似物CXCL8(3 - 72)K11R/G31P对CXCR1/2进行拮抗，通过抑制肿瘤细胞增殖和抑制血管生成来限制肺癌生长。
Oncotarget. 2015 Aug 28;6(25):21315-27. doi: 10.18632/oncotarget.4066.
7
Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.强效变构CXCR1/CXCR2拮抗剂Sch527123的药理学特性
J Pharmacol Exp Ther. 2007 Aug;322(2):477-85. doi: 10.1124/jpet.106.118927. Epub 2007 May 11.
8
G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.G31P，一种 CXC 趋化因子受体 1 和 2 的拮抗剂，可抑制裸鼠人前列腺癌细胞的生长。
Tohoku J Exp Med. 2012 Oct;228(2):147-56. doi: 10.1620/tjem.228.147.
9
Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.联合抗CXC受体1和2疗法通过减少中性粒细胞迁移和活化，是一种有前景的用于治疗呼吸系统疾病的抗炎疗法。
Pulm Pharmacol Ther. 2015 Oct;34:37-45. doi: 10.1016/j.pupt.2015.08.002. Epub 2015 Aug 10.
10
The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.CXCR1/CXCR2拮抗剂对轻度特应性哮喘患者中性粒细胞迁移的影响。
Pulm Pharmacol Ther. 2016 Dec;41:34-39. doi: 10.1016/j.pupt.2016.09.005. Epub 2016 Sep 14.
引用本文的文献
1
Current status and advances in the treatment of colorectal cancer with liver metastases.结直肠癌肝转移的治疗现状与进展
World J Clin Oncol. 2025 Jul 24;16(7):107438. doi: 10.5306/wjco.v16.i7.107438.
2
The CXCL1-CXCR2 Axis as a Component of Therapy Resistance, a Source of Side Effects in Cancer Treatment, and a Therapeutic Target.CXCL1-CXCR2轴作为治疗抵抗的一个组成部分、癌症治疗中副作用的一个来源以及一个治疗靶点。
Cancers (Basel). 2025 May 15;17(10):1674. doi: 10.3390/cancers17101674.
3
Neutrophils in cancer: At the crucial crossroads of anti-tumor and pro-tumor.癌症中的中性粒细胞：处于抗肿瘤与促肿瘤的关键十字路口。
Cancer Commun (Lond). 2025 Aug;45(8):888-913. doi: 10.1002/cac2.70027. Epub 2025 Apr 29.
4
The role of CXC chemokines and receptors in breast cancer.CXC趋化因子及其受体在乳腺癌中的作用。
Clin Exp Med. 2025 Apr 25;25(1):128. doi: 10.1007/s10238-025-01662-7.
5
Neutrophil and Colorectal Cancer.中性粒细胞与结直肠癌
Int J Mol Sci. 2024 Dec 24;26(1):6. doi: 10.3390/ijms26010006.
6
Neutrophil diversity and function in health and disease.中性粒细胞在健康与疾病中的多样性及功能。
Signal Transduct Target Ther. 2024 Dec 6;9(1):343. doi: 10.1038/s41392-024-02049-y.
7
A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELRCXCL-CXCR1/2 Pathway Inhibitor.一种通过ELRCXCL-CXCR1/2通路抑制剂抑制肿瘤生长和血管生成的有效解决方案。
ACS Med Chem Lett. 2024 Apr 3;15(6):845-856. doi: 10.1021/acsmedchemlett.4c00053. eCollection 2024 Jun 13.
8
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.CXCR2 拮抗剂纳瓦里辛联合帕博利珠单抗治疗特定晚期实体瘤的 2 期随机试验。
Invest New Drugs. 2024 Feb;42(1):145-159. doi: 10.1007/s10637-023-01410-2. Epub 2024 Feb 7.
9
Therapeutic inhibition of CXCR1/2: where do we stand?治疗性抑制 CXCR1/2：我们处于什么阶段？
Intern Emerg Med. 2023 Sep;18(6):1647-1664. doi: 10.1007/s11739-023-03309-5. Epub 2023 May 30.
10
Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer.小分子 CXCR2 和 CXCR1 拮抗剂抑制胰腺癌的肿瘤生长、血管生成和转移。
Cancer Lett. 2023 Jun 1;563:216185. doi: 10.1016/j.canlet.2023.216185. Epub 2023 Apr 14.
本文引用的文献
1
Cancer statistics, 2010.癌症统计数据，2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
2
Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.针对CXCR2和CXCR1的小分子拮抗剂通过降低肿瘤细胞增殖、存活及血管生成来抑制人黑色素瘤生长。
Clin Cancer Res. 2009 Apr 1;15(7):2380-6. doi: 10.1158/1078-0432.CCR-08-2387. Epub 2009 Mar 17.
3
A role for CXCR2 in senescence, but what about in cancer?CXCR2在细胞衰老中发挥作用，但在癌症中情况如何呢？
Cancer Res. 2009 Mar 15;69(6):2167-70. doi: 10.1158/0008-5472.CAN-08-3772. Epub 2009 Mar 10.
4
The good and the bad of chemokines/chemokine receptors in melanoma.趋化因子/趋化因子受体在黑色素瘤中的利弊
Pigment Cell Melanoma Res. 2009 Apr;22(2):175-86. doi: 10.1111/j.1755-148X.2009.00554.x. Epub 2009 Feb 14.
5
The interleukin-8 pathway in cancer.癌症中的白细胞介素-8信号通路。
Clin Cancer Res. 2008 Nov 1;14(21):6735-41. doi: 10.1158/1078-0432.CCR-07-4843.
6
CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing.CXC趋化因子及其受体：在皮肤伤口愈合中具有重要生物学作用的实例
Histol Histopathol. 2008 Nov;23(11):1399-407. doi: 10.14670/HH-23.1399.
7
The "seed and soil" hypothesis revisited.再探“种子与土壤”假说。
Lancet Oncol. 2008 Aug;9(8):808. doi: 10.1016/S1470-2045(08)70201-8.
8
VEGF-targeted therapy: mechanisms of anti-tumour activity.血管内皮生长因子靶向治疗：抗肿瘤活性机制
Nat Rev Cancer. 2008 Aug;8(8):579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3.
9
Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment.趋化因子与癌症：微环境中的迁移、细胞内信号传导及细胞间通讯
Biochem J. 2008 Feb 1;409(3):635-49. doi: 10.1042/BJ20071493.
10
Chemokines in tumor angiogenesis and metastasis.趋化因子在肿瘤血管生成和转移中的作用
Cancer Metastasis Rev. 2007 Dec;26(3-4):453-67. doi: 10.1007/s10555-007-9068-9.
Zotero 插件